Reimbursement Decisions Logo
Guest | Login/Register
Your foremost guide to global pricing and reimbursement decisions.TM

Canadian Drug Review Reimbursement Decision

Back to Decisions Master Page
Generic roflumilast
Company Nycomed Canada Inc.
Indication COPD
Condition Respiratory
Submission Type
Patient Population Roflumilast has a Health Canada indication for add-on therapy to bronchodilator treatment for the maintenance treatment of severe COPD associated with chronic bronchitis (i.e., patients with a history of chronic cough and sputum) in adult patients with a history of frequent exacerbations. Roflumilast is a selective inhibitor of the enzyme phosphodiesterase 4. It is available as a 500 mcg tablet and the Health Canada-approved dose is 500 mcg daily.
Status Complete
Date of Recommendation 2011-07-27
Recommendation Summary Do not list
Recommendation Details The Canadian Expert Drug Advisory Committee (CEDAC) recommends that roflumilast not be listed
Reason for Recommendation 1. In the two double-blind randomized controlled trials (RCTs), in the patient population for which roflumilast is approved, there were no statistically significant differences between roflumilast and placebo in the clinical outcomes of: severe chronic obstructive pulmonary disease (COPD) exacerbations, quality of life, or mortality. 2. In the two double-blind RCTs, differences between roflumilast and placebo for the coprimary outcomes (pre-bronchodilator forced expiratory volume in one second [FEV1] and the rate of moderate or severe COPD exacerbations) were small. Of Note: Neither RCT included an active comparator, therefore the trials were considered to have limited clinical relevance for patients with severe COPD because they disallowed concomitant treatment with long-acting anticholinergics and/or inhaled corticosteroids
Clinical Report:
Pharmacoeconomic Report:
Final Recommendation Report: CDR clinical report  CADTH-CDR Final Recommendation report

†The information referenced on this page is compiled from publicly available documents published by CADTH and is available through the embedded links.

Back to Decisions Master Page